Alpine Immune Sciences, Inc.
ALPNDelisted May 20, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001626199
Alpine Immune Sciences, Inc. was delisted on May 20, 2024; its insiders filed their last Form 4 on May 20, 2024; 180 institutions reported holding it in 13F filings for Q1 2024, worth $2.56B in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Alpine Immune Sciences, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Alpine Immune Sciences, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Cui Xiangmin | Director, 10% Owner | 0Indirect | May 20, 2024 | 0 |
| Decheng Capital China Life Sciences USD Fund III, L.P. | 10% Owner | 0Indirect | May 20, 2024 | 0 |
| Decheng Capital Management III (Cayman), LLC | 10% Owner | 0Indirect | May 20, 2024 | 0 |
| Decheng Capital Global Healthcare Fund (Master), LP | 10% Owner | 0Indirect | May 20, 2024 | 0 |
| Decheng Capital Global Healthcare GP, LLC | 10% Owner | 0Indirect | May 20, 2024 | 0 |
| OrbiMed Advisors LLC | Director | 0Indirect | May 20, 2024 | 0 |
| OrbiMed Capital GP VI LLC | Director | 0Indirect | May 20, 2024 | 0 |
| OrbiMed Genesis GP LLC | Director | 0Indirect | May 20, 2024 | 0 |
| Conway Robert E | Director | 0Indirect | May 20, 2024 | 0 |
| Gold Mitchell | Executive Chairman and CEO | 0 | May 20, 2024 | 0 |
| Topper James N | Director | 0Indirect | May 20, 2024 | 0 |
| Thompson Peter A. | Director | 0Indirect | May 20, 2024 | 0 |
| Rickey James Paul | See Remarks | 0 | May 20, 2024 | 0 |
| Peetz Christopher | Director | 0Indirect | May 20, 2024 | 0 |
| Peng Stanford L | See Remarks | 0 | May 20, 2024 | 0 |
| Hernday Natasha | Director | – | May 20, 2024 | 0 |
| Drappa Jorn | Director | – | May 20, 2024 | 0 |
| Durand Remy | Chief Business Officer | 0 | May 20, 2024 | 0 |
| Fuhs Ulrich Martin | Chief Accounting Officer | 0 | May 20, 2024 | 0 |
| Dummer Wolfgang | Chief Medical Officer | – | Oct 4, 2023 | 0 |
| Sandler Andrew Seth | Chief Medical Officer | – | Jan 5, 2023 | 0 |
| Venkatesan Jay | Director, 10% Owner | 238,126 | Jul 19, 2022 | 0 |
| Heron Patrick J | 10% Owner | 1,484,115 | Feb 15, 2022 | 0 |
| Frazier Life Sciences VIII, L.P. | 10% Owner | 1,484,115 | Feb 15, 2022 | 0 |
| FHM Life Sciences VIII, L.P. | 10% Owner | 1,484,115 | Feb 15, 2022 | 0 |
| FHM Life Sciences VIII, L.L.C. | 10% Owner | 1,484,115 | Feb 15, 2022 | 0 |
| Alpine ImmunoSciences, L.P. | 10% Owner | 2,600,980 | Sep 21, 2021 | 0 |
| Alpine Bioventures, GP, LLC | 10% Owner | 2,600,980 | Sep 21, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2024 (view filing) | Apr 25 | 4 days | Topper James NDirector | SSale | −19 | $64.57 | −$1.23K | 0.0%2.83M after | |
| Jan 29, 2024 (view filing) | Jan 25-26 | 4 days | Rickey James PaulSee Remarks | SSale | −118.0K | $23.31 | −$2.75M | −100.0%0 after | 3 lots10b5-1 |
| Dec 29, 2023 (view filing)4:18 PM ET | Dec 27-28 | 2 days | OrbiMed Advisors LLC and 2 othersDirector | SSale | −1.55M | $18.54 | −$28.7M | −85.4%264.3K after | 6 lotsDuplicate filing |
| Dec 29, 2023 (view filing) | Dec 28 | 1 day | Gold MitchellExecutive Chairman and CEO | SSale | −1.02K | $20.04 | −$20.4K | −100.0%0 after | 10b5-1 |
| Dec 29, 2023 (view filing) | Dec 27-28 | 2 days | Thompson Peter A.Director | SSale | −1.55M | $18.54 | −$28.7M | −85.4%264.3K after | 6 lots |
| Dec 27, 2023 (view filing)9:07 PM ET | Dec 22-27 | 5 days | Gold MitchellExecutive Chairman and CEO | SSale | −91.9K | $20.25 | −$1.86M | −100.0%0 after | 3 lots10b5-1 |
| Dec 21, 2023 (view filing)7:34 PM ET | Dec 19 | 2 days | Gold MitchellExecutive Chairman and CEO | SSale | −2.40K | $20.01 | −$48.1K | −100.0%0 after | 10b5-1 |
| Dec 21, 2023 (view filing) | Dec 19 | 2 days | Rickey James PaulSee Remarks | SSale | −15.2K | $19.21 | −$292.2K | −100.0%0 after | 10b5-1 |
| Dec 18, 2023 (view filing) | Dec 14-18 | 4 days | Rickey James PaulSee Remarks | SSale | −58.8K | $19.07 | −$1.12M | −100.0%0 after | 3 lots10b5-1 |
| Dec 12, 2023 (view filing)9:02 PM ET | Dec 8-12 | 4 days | Gold MitchellExecutive Chairman and CEO | SSale | −118.0K | $17.27 | −$2.04M | −100.0%0 after | 4 lots10b5-1 |
| Dec 6, 2023 (view filing) | Dec 4-6 | 2 days | Rickey James PaulSee Remarks | SSale | −70.8K | $16.06 | −$1.14M | −100.0%0 after | 3 lots10b5-1 |
| Dec 1, 2023 (view filing) | Nov 30 | 1 day | Rickey James PaulSee Remarks | SSale | −700 | $16.00 | −$11.2K | −100.0%0 after | 10b5-1 |
| Nov 14, 2023 (view filing)5:36 PM ET | Nov 9 | 5 days | Decheng Capital Global Healthcare Fund (Master), LP and 1 other10% Owner | PPurchase | +375.0K | $12.50 | +$4.69M | +27.6%1.74M after | Duplicate filing |
| Nov 14, 2023 (view filing) | Nov 9 | 5 days | Cui XiangminDirector, 10% Owner | PPurchase | +375.0K | $12.50 | +$4.69M | +27.6%1.74M after | |
| Nov 8, 2023 (view filing) | Nov 6 | 2 days | Rickey James PaulSee Remarks | SSale | −18.0K | $16.03 | −$288.6K | −100.0%0 after | 10b5-1 |
| Feb 15, 2022 (view filing)5:00 PM ET | Feb 11 | 4 days | Topper James N and 4 othersDirector, 10% Owner | PPurchase | +112.7K | $7.10 | +$800.0K | +8.2%1.48M after | |
| Jan 4, 2022 (view filing) | Dec 31, 2021 | 4 days | Rickey James PaulSenior VP and CFO | SSale | −17.0K | $13.92 | −$236.8K | −70.8%7.01K after | |
| Sep 27, 2021 (view filing) | Sep 23 | 4 days | Peetz ChristopherDirector | PPurchase | +1.90K | $10.17 | +$19.3K | New position1.90K after | Amended |
| Sep 27, 2021 (view filing) | Sep 23 | 4 days | Conway Robert EDirector | PPurchase | +15.0K | $10.08 | +$151.2K | +42.9%50.0K after | Amended |
| Sep 23, 2021 (view filing) | Sep 21 | 2 days | Conway Robert EDirector | PPurchase | +10.0K | $9.80 | +$98.0K | +40.0%35.0K after | |
| Sep 21, 2021 (view filing)6:42 PM ET | Sep 17 | 4 days | OrbiMed Advisors LLC and 2 othersDirector, 10% Owner | PPurchase | +1.01M | $9.40 | +$9.50M | New position425.5K after | 2 lotsDuplicate filing |
| Sep 21, 2021 (view filing)6:39 PM ET | Sep 17 | 4 days | Decheng Capital China Life Sciences USD Fund III, L.P. and 1 other10% Owner | PPurchase | +1.54M | $9.40 | +$14.5M | +48.7%4.71M after | Duplicate filing |
| Sep 21, 2021 (view filing)5:18 PM ET | Sep 17 | 4 days | Alpine ImmunoSciences, L.P. and 1 other10% Owner | SSale | −400.0K | $9.40 | −$3.76M | −13.3%2.60M after | Duplicate filing |
| Sep 21, 2021 (view filing) | Sep 17 | 4 days | Gold MitchellExecutive Chairman and CEO | SSale | −400.0K | $9.40 | −$3.76M | −13.3%2.60M after | Duplicate filing |
| Sep 21, 2021 (view filing) | Sep 17 | 4 days | Gold MitchellExecutive Chairman and CEO | SSale | −45.3K | $10.01 | −$453.1K | −29.3%109.4K after | |
| Sep 21, 2021 (view filing) | Sep 17 | 4 days | Venkatesan JayDirector, 10% Owner | SSale | −400.0K | $9.40 | −$3.76M | −13.3%2.60M after | |
| Sep 21, 2021 (view filing) | Sep 17 | 4 days | Cui XiangminDirector, 10% Owner | PPurchase | +1.54M | $9.40 | +$14.5M | +48.7%4.71M after | |
| Sep 21, 2021 (view filing) | Sep 17 | 4 days | Thompson Peter A.Director, 10% Owner | PPurchase | +1.01M | $9.40 | +$9.50M | New position425.5K after | 2 lots |
| Sep 17, 2021 (view filing) | Sep 15-16 | 2 days | Gold MitchellExecutive Chairman and CEO | SSale | −10.3K | $10.00 | −$102.5K | −6.2%154.6K after | 2 lots |